Exercise Changes to Peripheral Blood Mononuclear Cells in Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00585403|
Recruitment Status : Withdrawn (Nonapplicable clinical trial)
First Posted : January 3, 2008
Last Update Posted : January 25, 2021
|Condition or disease|
|Physical Fitness Obesity Child Development Growth|
To systematically measure for the first time in healthy children and adolescents the effects of brief bouts of exercise on:
- Numbers of circulating PMBCs, their subsets and key intercellular adhesion molecules (ICAMs).
- PBMC gene regulation of stress, inflammatory, and growth/repair mediators [including: interleukin-4 (IL-4), IL-6, IL-10, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma), growth hormone (GH), insulin-like growth factor-I (IGF-I), heat shock proteins (Hsp)].
- Circulating (serum) and intracellular PBMC levels of key mediators by flow cytometry and cell culture techniques.
- Circulating endogenous triggers of PBMC mediator responses-soluble Hsp, IL-6, and F2-isoprostanes.
- To determine how the acute PBMC responses are altered by gender, pubertal status, body composition (measured by whole-body and regional DEXA), and fitness (measured by progressive cycle ergometry and gas exchange).
- To determine the relationship in healthy children and adolescents among acute PBMC responses to exercise, biochemical precursors of the metabolic syndrome (insulin, glucose, lipids), and the balance of the TH1/TH2 immune response.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||PBMC, Exercise and Children: Initial Mechanisms|
|Study Start Date :||December 2004|
|Actual Primary Completion Date :||December 2004|
|Actual Study Completion Date :||December 2004|
Early and late pubertal girls and boys
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00585403
|United States, California|
|General Clinical Research Center|
|Orange, California, United States, 92868|
|Principal Investigator:||Dan M Cooper, M.D.||Univ. California, Irvine, CA|